DYADIC startet

http://www.ariva.de/news/...nd-Quarter-2013-Financial-Results-4743016 GrB  

1,94 $ +2,11% +0,04 $ In Euro: 1,4525 € | Nasdaq OTC Other, 16.08.13

haaaaach watt iss uns schön

buran & Dyadic,Die Börsen Schönheiten ansich  

1,85 $ +1,09% +0,02 $ In Euro: 1,39 € | Nasdaq OTC Other, 21.08.13

GrB  

1,90 $ +7,34% +0,13 $ In Euro: 1,4417 € | Nasdaq OTC Other, 06.09.13

das klingt doch nach Ostalgie ..iss aber USA .....schöner hype im Chart

buran,Die Börsen EVP KONSUM SECURITY  

Datum Erster Hoch Tief Schluss     Stücke Volumen
13.09.13 1,75 1,77 1,75  1,77 $ 3.100 5.427

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
16.10.13 1,57 1,67 1,57  1,67 $ 3.050 4.941

GrB  

All Debt Maturity Dates

16:15 18.10.13

PR Newswire

JUPITER, Fla., Oct. 18, 2013

JUPITER, Fla., Oct. 18, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic")(OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries, announced today that it has entered into agreements with all of its outstanding promissory note holders to extend their maturity dates to January 1, 2015.  The convertible portion of the debt, representing $6.8 million of the total $8.2 million outstanding principal, may be prepaid by Dyadic at any time in whole or in part, without penalty, after March 31, 2014 with 30 days notice.  In all other respects, the terms and conditions of these promissory notes remain unchanged and in full force and effect.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "The extension of our debt provides Dyadic with greater flexibility by allowing us the option to call the convertible debt early."

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.
Quelle: PR Newswire  

2013 Financial Results And Host Conference Call On Thursday, November 14, 2013

13:35 01.11.13

PR Newswire

JUPITER, Fla., Nov. 1, 2013

JUPITER, Fla., Nov. 1, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced that it will report its financial results for the third quarter ended September 30, 2013 after market close on Thursday, November 14, 2013 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

In order to participate in the live session, please use the following dial-in numbers five to ten minutes prior to start time:

Calling from the United States or Canada:  888-713-3595

Calling from other countries:  913-905-3226

Confirmation Code:  9272553

A replay of the conference call will be available on Dyadic's website (www.dyadic.com) within 24 hours after the live event.

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.
Quelle: PR Newswire  

SK 1,68 $ SKP +0,00 Pott +86,67% ,GrB
          §  

22:50 07.11.13

PR Newswire

JUPITER, Fla., November 7, 2013

JUPITER, Fla., November 7, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,551,751 B2 entitled, "BX11 Enzymes Having Xylosidase Activity" by the United States Patent and Trademark Office ("USPTO").

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

The invention relates to methods of developing and producing novel enzymes, more specifically for the development of a variety of fungal enzymes.  Also described in the patent is the encoding of nucleic acid molecules for such enzymes, compositions, recombinant, and genetically modified host cells, and methods of use.

In addition, the patent also addresses methods to convert lignocellulosic biomass into fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass.  Large amounts of carbohydrates in plant biomass provide a plentiful source of potential energy in the form of sugars that can be utilized to produce biofuels such as Cellulosic Ethanol and a variety of bio-based chemicals.  Additionally, the patent addresses methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, biorefining, deinking and biobleaching of paper and pulp, and treatment of waste streams.

Dyadic's President and CEO, Mark Emalfarb, stated, "This latest patent builds upon our family of patents that address the conversion of lignocellulosic biomass into fermentable sugars for the production of renewable biofuels and bio-based chemicals using our proprietary C1 technology. This latest patent adds to our comprehensive IP portfolio further protecting our C1 protein expression system and the products derived therefrom, which continues to attract blue chip customers, partners, and collaborators."

This patent is the thirteenth U.S. patent issued to Dyadic adding to its portfolio of 41 international patents, 23 pending international and 11 pending U.S. patent applications which cover various features of Dyadic's proprietary technologies.

The newly issued patent is accessible on the USPTO's website at www.uspto.gov or on Dyadic's website at www.dyadic.com.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.
Quelle: PR Newswire  

http://www.ariva.de/news/...rd-Quarter-2013-Financial-Results-4846796 GrB  

Zeit
                Kurs               Stück                    §
  18:57:49§1,58 $
               1.040                    §
  18:56:09§1,58 $
               1.000                    §
  18:46:06§1,59 $
                 400                    §
  18:45:55§1,59 $
                 308                    §
  18:45:48§1,59 $
                 200                    §
  18:22:54§1,59 $
               2.500                    §
  18:22:50§1,60 $
                 900                    §
  18:22:47§1,60 $
                 100                    §
  16:25:47§1,59 $
                 100                    §
  15:30:17§1,60 $
                 200                    §
  15:30:16§1,60 $
                 800                    §
  15:30:04§1,70 $
             200
§
buran und MfG und danke und weitermachen  

Zeit
          §Kurs Stück
16:16:40 1,55 $
          §1.000
16:01:44 1,60 $
          §1.800
15:51:59 1,55 $
          §800
15:51:41 1,60 $
          §1.085
15:51:21 1,60 $
          §500
15:44:55 1,60 $
          §200
15:30:55 1,66 $
          §4.400
15:30:52 1,60 $
          §100
15:30:12 1,45 $
          §800
15:30:10 1,61 $
          §1.000
15:30:04 1,44 $
              50
§
buran und MfG und danke und weitermachen  

Conferences In December 2013

22:15 21.11.13

PR Newswire

JUPITER, Fla., Nov. 21, 2013

JUPITER, Fla., Nov. 21, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI) ("Dyadic" or "the Company"), a global leader in the commercial application of biotechnology for the discovery, development and production of enzymes and other proteins, today announced that the Company will present at the following conferences:

   The LD Micro "Main Event" Conference, a premier small-cap conference to be held December 3-5, 2013 at the Luxe Hotel in Los Angeles, California.  On Wednesday, December 4, 2013, Dyadic Chairman and Chief Executive Officer Mark Emalfarb will present in Track Three at 10:00 a.m. PST.  Mr. Emalfarb will be available for individual meetings throughout the conference. For registration information, please visit the conference website at http://www.ldmicro.com.  
   Biotechnology Industry Organization's 2013 Pacific Rim Summit on Industrial Biotechnology and Bioenergy, to be held December 8-11, 2013 at the Westin Gaslamp Quarter in San Diego, California. On Monday, December 9, 2013, Dyadic Chief Operating Officer Danai Brooks will present at the "Development of New Industrial Enzymes" panel at Track 5 "Technical and Research Presentations" at 8:30-10:00 a.m. PST. Mr. Brooks will be available for individual meetings throughout the conference. For registration information, please visit the conference website at http://www.bio.org/events.  

To schedule a meeting with the Company, please contact its outside investor relations firm ICR at the number below.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.
Quelle: PR Newswire  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  29.11.13      1,68      1,69§1,65 1,68 $ 21.267 35.399

GrB  

Zeit


      Kurs               Stück                    §
  21:58:52§1,32 $
     4.000                    §
  21:12:06§1,35 $
     1.000                    §
  20:37:28§1,35 $
     2.000                    §
  20:37:25§1,35 $
     1.000                    §
  20:25:28§1,29 $
     1.500                    §
  20:21:34§1,30 $
     3.400                    §
  20:19:03§1,29 $
     1.100                    §
  20:18:55§1,29 $
     1.000                    §
  20:18:54§1,30 $
     2.400                    §
  20:14:54§1,30 $
       500                    §
  20:14:11§1,30 $
     1.000                    §
  19:25:21§1,29 $
       100                    §
  19:13:32§1,30 $
       100                    §
  19:13:15§1,30 $
     3.800                    §
  19:13:12§1,30 $
       100                    §
  19:12:38§1,30 $
     1.000                    §
  18:39:35§1,295 $
     9.300                    §
  18:39:28§1,30 $
       100                    §
  18:20:20§1,305 $
     1.700                    §
  18:20:09§1,31 $
       800                    §
  17:43:59§1,305 $
     6.215                    §
  17:41:30§1,30 $
       600                    §
  17:41:02§1,27 $
     4.250                    §
  17:28:04§1,26 $
       427                    §
  17:14:53§1,26 $
     1.600                    §
  17:14:42§1,27 $
     2.900                    §
  17:14:39§1,27 $
       100                    §
  17:14:37§1,27 $
       300                    §
  17:05:34§1,27 $
       590                    §
  17:01:41§1,27 $
     1.780                    §
  17:01:34§1,27 $
       100                    §
  17:00:52§1,27 $
       100                    §
  16:58:11§1,25 $
       693                    §
  16:49:37§1,27 $
     1.000                    §
  16:49:21§1,30 $
     1.020                    §
  16:42:00§1,30 $
       480                    §
  16:27:34§1,305 $
     2.900                    §
  16:27:29§1,31 $
       100                    §
  16:21:47§1,31 $
     3.000                    §
  16:21:37§1,34 $
     2.000                    §
  16:21:23§1,35 $
     5.500                    §
  16:10:32§1,30 $
       850                    §
  16:10:09§1,30 $
       300                    §
  16:10:05§1,30 $
       850                    §
  16:10:04§1,35 $
     4.000                    §
  16:10:03§1,30 $
       300                    §
  16:08:00§1,35 $
     1.400                    §
  16:07:50§1,35 $
       100                    §
  16:07:06§1,35 $
     2.500                    §
  16:07:03§1,35 $
       100                    §
  16:06:36§1,35 $
     1.400                    §
  16:04:08§1,355 $
       800                    §
  16:03:21§1,35 $
     1.339                    §
  15:51:37§1,355 $
     1.161                    §
  15:50:38§1,35 $
       400                    §
  15:45:27§1,355 $
     2.000                    §
  15:30:07§1,35 $
       100                    §
  15:30:06§1,35 $
100
GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  24.01.14      1,49      1,50§1,30 1,47 $ 33.692 48.571

GrB  

Number of Tickers: 245
Date: 27-Jan-14
Contributor:§ValuEngine, Inc.
    Title:§ValuEngine Industry Report for Medical-biomed/genetics
Document Size: 18 pages
Price: $49
Document Type: Adobe Acrobat Reader®
Download free Adobe Acrobat Reader®
http://reports.finance.yahoo.com/w0?r=50217056:1  

http://finance.yahoo.com/q?s=dyai&ql=1 GrB  

Revenue (ttm): 15.74M
Revenue Per Share (ttm): 0.49
Qtrly Revenue Growth (yoy): 37.30%
Gross Profit (ttm): 7.99M
EBITDA (ttm)6: -142.66K
Net Income Avl to Common (ttm): -1.33M
Diluted EPS (ttm): -0.04
Qtrly Earnings Growth (yoy): N/A
http://finance.yahoo.com/q/ks?s=DYAI+Key+Statistics  

SK 1,47 $ SKP -0,68 Pott +63,33% buran und MfG und DYADIC startet


 

http://www.ariva.de/news/...C1-License-Agreement-With-Codexis-4958082 GrB  

on OTCQX®12:06 11.03.14


PR Newswire

NEW YORK, March 11, 2014

NEW YORK, March 11, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Dyadic International, Inc. (OTCQX: DYAI), a global biotechnology company, has been approved to trade on OTCQX®, the best marketplace with qualified companies.

Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO

Dyadic begins trading today on OTCQX U.S. Premier, a segment of the OTCQX marketplace reserved for world-leading U.S. companies that meet financial standards and provide timely news and disclosure to investors.  Investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"We are pleased to welcome Dyadic to the OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "Dyadic joins the growing U.S. companies that have chosen OTCQX to provide their investors with transparent trading and convenient access to their news and disclosure.  We look forward to working with Dyadic's management team as they continue to grow their company and enhance their value to shareholders."  

Dyadic's Chief Financial Officer, Michael Faby, stated, "Joining OTCQX clearly demonstrates our commitment to providing our shareholders access to a trading platform that we think will attract larger institutional investors and generate greater market interest in Dyadic."

B. Riley & Co., LLC serves as Dyadic's Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing professional guidance on OTCQX requirements.

Dyadic International is a global biotechnology company headquartered in Jupiter, Florida with operations in the United States and the Netherlands.  The company uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

Dyadic will trade in the U.S. on OTCQX under the symbol "DYAI."

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace with Qualified Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The Open Marketplace with Variable Reporting Companies. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link® ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

SOURCE OTC Markets Group Inc.


Quelle: PR Newswire  

Dyadic International Joins OTCQX Marketplace13:35 11.03.14


PR Newswire

JUPITER, Fla., March 11, 2014

JUPITER, Fla., March 11, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company, today announced that it has been approved for trading on OTCQX, the best marketplace for qualified companies.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Shares of Dyadic begin trading today on OTCQX U.S. Premier, a segment of the OTCQX marketplace reserved for world-leading U.S. companies that meet financial standards and provide timely news and disclosures to investors.  Investors can find current financial disclosure and Real-Time Level 2 quotes for Dyadic on www.otcmarkets.com.

Dyadic's Chief Financial Officer, Michael Faby stated, "Joining OTCQX clearly demonstrates our commitment to providing our shareholders access to a trading platform that we think will attract larger institutional investors and generate greater market interest in Dyadic."

Dyadic's Chief Executive Officer, Mark Emalfarb added, "Our admission to OTCQX is just the next step to Dyadic once again becoming an SEC reporting company traded on a registered national exchange.  While we continue to evaluate our uplisting opportunities, we believe this step shows our commitment to full transparency, to providing our shareholders greater liquidity, and access to one of the most trusted and reliable trading platforms available today."

Dyadic has retained B. Riley & Co., LLC to serve as its Investment Banking Designated Advisor for Disclosure ("DAD").

Dyadic will continue to trade under the symbol "DYAI."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, our licensing strategy and becoming an SEC reporting company may constitute forward-looking statements. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements in this press release. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; and (4) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Initial Information and Disclosure Statement to be filed with the OTC Markets Group.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

http://www.ariva.de/news/...-Full-Year-2013-Financial-Results-4962451 GrB